Ascelia Pharma recently announced its maiden interim financial results as a public company. Q319 operational expenditure and net loss has increased versus Q318 due to the Phase III study preparation and IPO costs. It is interesting to see a company with a clinical pipeline appear on the public market. Ascelia’s first product is Phase III ready with a sophisticated regulatory strategy.
Written by
Ascelia Pharma |
A specialty oncology company emerges
|
Healthcare |
QuickView
21 May 2019 |
Share price graph
Share details
Business description
Bull
Bear
Analyst
|
||||||||||||||||||||||
Ascelia Pharma recently announced its maiden interim financial results as a public company. Q319 operational expenditure and net loss has increased versus Q318 due to the Phase III study preparation and IPO costs. It is interesting to see a company with a clinical pipeline appear on the public market. Ascelia’s first product is Phase III ready with a sophisticated regulatory strategy.
Interim financial results
The maiden financial report of a newly listed company is largely cosmetic and an update of the recent prospectus. In Ascelia’s case, the Q319 results announcement noted an increased operating loss of SEK11.7m (SEK4.4m in Q318) due to the preparations for the Phase III study and the IPO costs. R&D and administrative costs comprised virtually all the SEK11.6m loss for Q319, excluding the R&D tax rebate. Ascelia reported a robust Q319 SEK219m cash position (SEK55m at the end of Q318) after raising SEK180m at the IPO at SEK25 per share. The Mangoral Phase III study is now fully funded with results expected around the end of 2020.
Lead product Mangoral about to start Phase III
At a point in the market where US life science IPOs are often preclinical, it is refreshing to see a European emerging specialty pharma oncology company come to the public markets with a mature clinical pipeline. The lead product – the imaging agent Mangoral – is being studied in the detection of liver tumours. Phase III for Mangoral has a primary endpoint of the detection of lesions by MRI (with and without Mangoral) and the study only has a 72-hour safety follow up. This means that Mangoral could have a label that includes both primary and secondary liver cancer detection. The Phase III study is not dependent on a long follow up (which would be costly) or a liver biopsy to confirm the cancer, which tends to restrict recruitment in drug studies in other liver indications. Outside oncology, non-alcoholic steatohepatitis is a potentially large market that is being restrained by its definitive diagnosis. If Mangoral can detect both fibrotic and cancerous liver lesions, it will be a significant advance.
Valuation: Not yet appreciated by the market
Recent IPOs may not be efficiently valued. However, with an enterprise value of only SEK244m, one Phase III-ready imaging product and one Phase II-ready oral oncology drug (Oncoral for gastric cancer) and a market capitalisation that is half cash, this appears to be a very low pipeline valuation. The average EV for three recent preclinical US IPOs is SEK1.82bn ($184m), which highlights the valuation disparity between US and European life science companies.
|
Historical financials
Source: Ascelia Pharma |
EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.
|
Disclaimer
|
||||||||||
|
Disclaimer
|
||||||||||
Research: Industrials
Having delivered management expectations in FY18 and despite tempering our forecasts modestly for FY19, guidance is still indicating strong growth, especially at Voltabox. Q119 results do nothing to deflect the expectations and growth should accelerate as the year progresses, primarily as Voltabox increasingly delivers against its €1.1bn backlog. The continued investment in the auto operations should also start to be reflected in improved earnings this year. On our new lower estimates, the rating fails to reflect the growth potential.